



Apr 8, 2020
FunPep Co., Ltd.

**AnGes and Osaka University to jointly develop DNA vaccine for COVID-19:
FunPep to participate in the development of next-generation vaccines using peptide technology**

FunPep Co., Ltd. (FunPep), a start-up company from Osaka University, is pleased to announce that it will participate in the joint development of a DNA vaccine for COVID-19 with Osaka University and AnGes, Inc. (AnGes), with the aim of developing a next-generation vaccine using peptide technology. FunPep is advancing the development of vaccines using peptide technology that utilizes FunPep's proprietary adjuvant, which is already in clinical trials overseas. By using FunPep's peptide technology, the company aims to develop next-generation vaccines with higher antibody production capacity and efficacy. By incorporating antibody-inducing peptides into the vaccine being developed by Osaka University and AnGes, antibody production is expected to be improved, which is expected to provide clinical benefits such as a reduction in the amount and frequency of vaccine administration, stronger infection prevention, and less severe infections.

【Participation in the development of the COVID-19 Vaccine】

- FunPep is advancing research on antibody-inducing peptides using AJP001 (a peptide that shows adjuvant-like activity), a product of Osaka University research, with Osaka University (Clinical Gene Therapy, Health and Developmental Medicine), and is already conducting clinical trials overseas.
- With the aim of developing next-generation vaccines with greater antibody production capabilities and efficacy, FunPep is conducting joint research with Osaka University and AnGes to combine DNA vaccines with AJP001, which has adjuvant-like effects (increases immune response and enhances efficacy), or with an antibody-inducing peptide that combines AJP001 with an epitope (an antigenic peptide of part of the COVID-19 virus).